Anlon Healthcare Stock Screener | Share Price & Fundamental Analysis
AHCL
Pharmaceuticals
Share Price NSE
₹125.73
▼
-3.13 (-2.43%)
Share Price BSE
₹125.85
▼
-3.40 (-2.63%)
Track Anlon Healthcare share price live with TickJournal's free stock screener.
Analyze Anlon Healthcare share price history trends and compare 52-week high low
levels.
Calculate AHCL stock fair value using fundamental analysis and view live share price charts.
Determine Anlon Healthcare share intrinsic value and compare it with current AHCL share price.
Record your Anlon Healthcare trades in TickJournal's free trading journal and track your portfolio performance.
Anlon Healthcare Market Cap
₹579.25 Cr.
AHCL P/E Ratio (TTM)
16.64
EPS (TTM)
₹6.37
Dividend Yield
-
Debt to Equity
1.46
AHCL 52 Week High
₹154.70
Anlon Healthcare 52 Week Low
₹106.64
Operating Margin
29.00%
Profit Margin
20.59%
AHCL Revenue (TTM)
₹170.00
EBITDA
₹50.00
Net Income
₹35.00
Total Assets
₹181.00
Total Equity
₹80.00
Anlon Healthcare Share Price History - Stock Screener Chart
Screen AHCL historical share price movements with interactive charts. Analyze price trends and patterns.
Anlon Healthcare Company Profile - Fundamental Screener
Screen Anlon Healthcare company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AHCL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0Y8W01017
Anlon Healthcare Balance Sheet Screener
Screen AHCL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 181 | 128 | 112 | 85 | 71 |
| Current Assets | 159 | 101 | 86 | 58 | 40 |
| Fixed Assets | 23 | 27 | 26 | 27 | 29 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 41 | 57 | 61 | 55 | 38 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 80 | 21 | 7 | 2 | 2 |
| Share Capital | 40 | 16 | 12 | 12 | 12 |
| Reserves & Surplus | 41 | 5 | -5 | -10 | -10 |
Anlon Healthcare Income Statement Screener - Profit & Revenue Analysis
Screen Anlon Healthcare income statement and profit fundamentals.
Analyze AHCL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Anlon Healthcare share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|---|
| Revenue | 170 | 121 | 67 | 113 | 58 | 16 |
| Expenses | 121 | 88 | 51 | 101 | 52 | 21 |
| EBITDA | 50 | 32 | 16 | 13 | 6 | -5 |
| Operating Profit % | 29.00% | 27.00% | 23.00% | 11.00% | 9.00% | -33.00% |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 4 | 4 | 4 | 4 | 4 | 3 |
| Profit Before Tax | 44 | 27 | 10 | 7 | 0 | -10 |
| Tax | 9 | 6 | 0 | 1 | 0 | 0 |
| Net Profit | 35 | 21 | 10 | 6 | 0 | -10 |
| EPS | 8.40 | 6.37 | 6.68 | 4.85 | -0.09 | -8.53 |
Anlon Healthcare Cash Flow Screener - Liquidity Fundamentals
Screen AHCL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | -23 | -3 | -3 | -2 | -15 |
| Investing Activities | 3 | -3 | 0 | 0 | -3 |
| Financing Activities | 19 | 8 | 2 | 3 | 16 |
| Net Cash Flow | -1 | 2 | -1 | 1 | -2 |
Anlon Healthcare Shareholding Pattern Screener
See Anlon Healthcare shareholding pattern with promoter, FII, and DII holdings.
Check Anlon Healthcare promoter holding and ownership changes for AHCL on TickJournal.
| Item | 2025-Apr | 2025-Jun | 2025-Aug | 2025-Sept | 2025-Dec | 2024-Oct |
|---|---|---|---|---|---|---|
| Promoter Holding | 70.26% | 52.68% | 70.26% | 52.68% | 52.68% | 70.26% |
| FII Holding | 0.00% | 14.42% | 0.00% | 0.00% | 0.23% | 0.00% |
| DII Holding | 0.00% | 4.35% | 0.00% | 2.83% | 4.49% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 0.00% | 14.64% | 0.00% | 20.73% | 23.58% | 0.00% |
| Other Holding | 29.74% | 13.92% | 29.74% | 23.75% | 19.02% | 29.74% |
| Shareholder Count | 131 | 9,125 | 135 | 9,126 | 11,412 | 109 |
Anlon Healthcare Share Dividend Screener - Share Yield Analysis
Check Anlon Healthcare dividend history with payout and yield data.
View Anlon Healthcare dividend details including ex-dates and amounts for AHCL stock.
Anlon Healthcare Stock Index Membership
See which indices include Anlon Healthcare stock.
Check AHCL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Anlon Healthcare Market Events Screener - Corporate Actions
Get Anlon Healthcare corporate actions including splits, bonuses, and buybacks.
Check Anlon Healthcare stock events that may affect AHCL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 4.07% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 2.44% |
Anlon Healthcare Competitors Screener - Peer Comparison
Screen AHCL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 419,092 | 38.07 | 54,729 | 9.71% | 10,980 | 55.50 |
| Divis Laboratories | 168,387 | 68.67 | 9,712 | 18.67% | 2,191 | 57.58 |
| Torrent Pharmaceuticals | 147,004 | 64.61 | 11,539 | 6.99% | 1,911 | 65.06 |
| Cipla | 108,250 | 24.01 | 28,410 | 7.12% | 5,291 | 47.64 |
| Dr Reddys Laboratories | 106,541 | 19.45 | 33,741 | 16.73% | 5,725 | 55.60 |
| Lupin | 104,488 | 22.53 | 22,910 | 13.74% | 3,306 | 66.87 |
| Mankind Pharma | 91,956 | 51.46 | 12,744 | 20.90% | 2,007 | 63.52 |
| Zydus Life Science | 90,516 | 18.47 | 23,511 | 18.55% | 4,615 | 55.01 |
| Aurobindo Pharma | 69,760 | 20.36 | 32,346 | 9.43% | 3,484 | 58.41 |
| Alkem Laboratories | 66,113 | 27.83 | 13,458 | 3.70% | 2,216 | 51.36 |
Anlon Healthcare Company Announcements - News Screener
Screen AHCL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Closure of Trading Window | View | |
| Board Meeting Intimation for Stock Split And Issue Of Bonus Shares | View | |
| 2026-03-08 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | View |
| 2026-03-04 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-02-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-09 | Approval Of Appointment Of Mr. Naimish Dilipbhai Bhatt As A Chief Financial Officer Of The Company. | View |
| 2026-02-09 | Approval Of Resignation Of Mr. Shailesh Kantilal Thakkar Independent Director Of The Company. | View |
| 2026-02-09 | Appointment Of Mr. Kishan Vinodkumar Raja As A Independent Director | View |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Resignation of Director | View |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | View |
| 2026-02-09 | Anlon Helthcare Limited_Financial Results For The Quarter Ended December 31 2025 | View |
| 2026-02-09 | Board Meeting Outcome for Outcome Of Board Meeting For The Approval Of Financial Results For The Quarter Ended December 31 2025 | View |
| 2026-02-05 | The Company Has Purchased A Commercial Office At Ahmedabad Gujarat And Shall Be Used For Marketing Office. | View |
| 2026-02-03 | Board Meeting Intimation for Consideration And Approve The Financial Results For The Quarter Ended December 31 2025 | View |
| 2026-01-28 | Intimation As Per Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (The Listing Regulations) - Development Of New Product | View |